IDH1 and cholangiocarcinoma: The mutant IDH1 inhibitor ivosidenib was simultaneously evaluated in patients with AML in a single-arm phase I study [31], a randomized double-blind phase III study in patients with cholangiocarcinoma [32], and a single-arm phase I trial in patients with myelodysplastic syndrome [33], leading to FDA approvals for these indications in 2018, 2021, and 2023, respectively.